Do patients with Parkinson’s disease benefit from embryonic dopamine cell transplantation?
- Cite this article as:
- Freed, C.R., Leehey, M.A., Zawada, M. et al. J Neurol (2003) 250(Suppl 3): iii44. doi:10.1007/s00415-003-1308-5
- 161 Downloads
Embryonic dopamine cell transplants survive in nearly all patients regardless of age and without immunosuppression. Transplants can improve Parkinson “off” symptoms up to the best effects of L-dopa observed preoperatively. They cannot improve the “best on” state. Transplants appear to survive indefinitely. In 10 to 15% of patients, transplants can reproduce the dyskinetic effects of L-dopa even after discontinuing all L-dopa. Neurotransplantation should be tried earlier in the clinical course of Parkinson’s to see if earlier intervention can prevent progression of the disease, particularly the dyskinetic responses seen after longterm L-dopa treatment.